The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19

Camila Rosat Consiglio[1,9], Nicola Cotugno[2,3,9], Fabian Sardh[4,9], Christian Pou[1,9], Donato Amodio[2,3,9], Sonia Zicari[2], Alessandra Ruggiero[2], Giuseppe Rubens Pascucci[2], Lucie Rodriguez[1], Veronica Santilli[2,5], Ziyang Tan[1], Daniel Eriksson[4,6], Jun Wang[1], Alessandra Marchesi[5], Tadepally Lakshmikanth[1], Andrea Campana[5], Alberto Villani[5], Paolo Rossi[3,5], the CACTUS study team, Nils Landegren[4,7,9], Paolo Palma[2,3,9], Petter Brodin[1,7,9,10]

[1] Science for life Laboratory, Dept. of Women's and Children Health, Karolinska Institutet, Sweden.

[2]Research Unit of Congenital and Perinatal Infections, Bambino Gesù Children's Hospital, Rome, Italy.

[3] Chair of Pediatrics, Dept. of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.

[4]Department of Medicine (Solna), Karolinska University Hospital, Karolinska Institutet, Sweden.

[5]Academic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

[6]Department of Immunology, Genetics and Pathology, Uppsala University and Department of Clinical Genetics, Uppsala University Hospital, Uppsala, Sweden

[7]Science for life Laboratory, Department of Medical Sciences, Uppsala University, Sweden.

[8] Pediatric Rheumatology, Karolinska University Hospital, Sweden.

[9] Equal contribution

[10] Lead contact

Correspondence: petter.brodin@ki.se, paolo.palma@opbg.net, nils.landegren@ki.se

Keywords: SARS-CoV2, COVID-19, Kawasaki disease, Multi-system inflammatory syndrome in children, MIS-C, Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2, PIMS-TS, Systems immunology, human immunology, autoantibodies, immunoglobulin

SUMMARY

SARS-CoV2 infection is typically very mild and often asymptomatic in children. A complication is the rare Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19, presenting 4-6 weeks after infection as high fever and organ dysfunction and strongly elevated markers of inflammation. The pathogenesis is unclear but has overlapping features with Kawasaki disease suggestive of vasculitis and a likely autoimmune etiology. We apply systems-level analyses of blood immune cells, cytokines and autoantibodies in healthy children, children with Kawasaki disease enrolled prior to COVID-19, children infected with SARS-CoV2 and children presenting with MIS-C. We find that the inflammatory response in MIS-C differs from the cytokine storm of severe acute COVID-19, is more similar to Kawasaki disease, but also differ from this with respect to T-cell subsets, IL-17A and biomarkers associated with arterial damage. Finally, autoantibody profiling suggests endoglin, an endothelial glycoprotein as one of several candidate targets of autoantibodies in MIS-C.

HIGHLIGHTS

Hyperinflammation in MIS-C differs from that of acute COVID-19

T-cell subsets discriminate Kawasaki disease patients from MIS-C

IL-17A drives Kawasaki, but not MIS-C hyperinflammation.

Autoantibodies to Endoglin are elevated in MIS-C and a subset of Kawasaki patients

INTRODUCTION



Figure 1. Systems-level analyses in children with COVID-19, Kawasaki disease and MIS-C

The severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), first emerged in Wuhan in December 2019 (Huang et al., 2020) spread broadly to Europe and in particular to the northern regions of Italy in the beginning of February 2020. The first reports from China showed that children presented with milder symptoms as compared to adults infected by SARS-CoV-2 (Lu et al., 2020). Reasons for these differences are mostly unknown, but several theories have been discussed, involving immune system differences, cross-reactive immunity to more common coronaviruses, differences in expression levels of the viral entry receptor ACE2, as well as a better overall health among children as compared to the elderly (Brodin, 2020). The mild COVID-19 in children has been confirmed also in areas with very high disease prevalence such as northern Italy (Parri et al., 2020). The mild COVID-19 disease course in children is now challenged by a few recent reports of children presenting with a severe hyperinflammatory syndrome in United Kingdom (Riphagen et al., 2020; Whittaker et al., 2020), Italy (Verdoni et al., 2020) and New York City (Cheung et al., 2020). In these case series children present with high fevers, and some symptoms previously associated with Kawasaki disease such as conjunctivitis, lymphadenopathy, mucocutaneous rash and coronary artery dilation and in severe cases cardiovascular chock and signs of encephalitis.

Kawasaki disease is an acute vasculitis with highest incidence in children younger than 5 years old and it is the leading cause of acquired heart disease in developed countries where streptococcal infections are usually treated, and rheumatic fevers are rare (Shulman and Rowley, 2015). Kawasaki disease has a particularly high incidence in children with East Asian ancestry. The dominating theory for the pathophysiology of Kawasaki disease involves the production of self-reactive antibodies during an acute immune response to a virus, probably at mucosal surfaces and IgA-producing plasma cells have been found within

the arterial wall (Rowley et al., 2008). Neutrophils infiltrate and a necrotizing arteritis develops with the destruction of connective tissue components and arterial dilation as a result (Shulman and Rowley, 2015). Efforts made to define the pathogenesis of Kawasaki also revealed an imbalance of IL-17-producing T-cells and regulatory T-cells during acute phase of the disease (Jia et al., 2010).

Given the severity of the Multisystem Inflammatory Syndrome in children (MIS-C) associated with COVID-19, and the uncertain development of this pandemic it is urgent to better reveal the pathogenesis of MIS-C. Novel treatment strategies of such critically ill children be devised. Here we have performed a systems-level analysis of immune cells, cytokines and antibodies in the blood of healthy children, children with Kawasaki disease enrolled prior to the COVID-19 pandemic, children infected with SARS-CoV2, and children with MIS-C (**Figure 1**). We reveal several facets of the hyperinflammatory state in MIS-C, contrasting both the hyperinflammation seen in adults with acute SARS-CoV2 infection, as well as in children with classical Kawasaki disease and suggest autoantibody targets possibly involved in the pathogenesis of this new disease.

RESULTS

Children with SARS-CoV2, MIS-C and Kawasaki disease

We enrolled 44 children with COVID-19 in Italy in 2020. Four of these developed MIS-C. The 40 SARS-CoV2+ children without MIS-C are denoted as CoV2+ children (**Table 1**). We compare children with COVID-19 to 28 children with Kawasaki disease enrolled and sampled prior to the COVID-19 pandemic. Children with MIS-C were significantly older than children with Kawasaki disease (**Table 1**). No statistical differences were found in terms of gender among the groups of children. Both MIS-C and CoV2+ children presented with lower white blood cell counts (WBC) as compared to patients with Kawasaki disease (**Table 1**). Lymphopenia is a hallmark of COVID-19 and was more pronounced in MIS-C than in CoV2+ children with mild disease, and also more than in Kawasaki disease (**Table 1**). MIS-C patients also differed in their ferritin levels which were markedly higher as compared to both Kawasaki disease and CoV2+ (**Table 1**). These observations are in line with recent clinical reports of larger sets of patients (Whittaker et al., 2020), suggesting that our cohort is representative of patients with MIS-C, Kawasaki disease and children with mild SARS-CoV2-infection.

	Children with COVID-19 (n= 44)		Kawasaki (KD) (n= 28)	Healthy (HC) (n= 12)	p-value
	CoV2+ (n= 40)	MIS-C (n= 4)			
Age in months (range)	80.2 (0.3-207)	172,1 (137,3-206,53)	24.5 (13.5-47.75)	33.0 (26.5-56.2)	p= 0.0001 (MIS-C vs KD) p= 0.0006 (CoV2+ vs KD) p= 0.018 (CoV2+ vs MIS-C) p<0.01 between HC, KD and Cov2+ groups
Male : Female	23 : 17	3 : 1	14 : 10	9 : 9	n.s
Platelets, 10^3/µL (range)	246 (200-299)	238.8 (158.5-312.3)	387.0 (268.5-495.8)	372.0 (284.0-422.8)	p= 0.0006 (CoV2+ vs KD)
WBC, 10^3/µL (range)	6.4 (5.1-9.8)	7.4 (5.4-18)	15.0 (10.6-19.6)	9.17 (7.7-9.7)	p= 0.0014 (CoV2+ vs KD); p<0.01 HC vs KD, MIS-C.
Neutrophils, 10^3/µL (range)	2.3 (1.5-3.2)	8.1 (2.7-15.7)	10.0 (6.3-13.0)	2.5 (1.9-6.1)	p= 0.0001(CoV2+ vs KD); p= 0.023 (CoV2+ vs MIS-C)
Lymphocytes, 10^3/µL (range)	2.7 (1.8-4.3)	0.95 (0.7-1.9)	2.4 (1.3-4.7)	4.7 (3.8-5.8)	p= 0.038 (MIS-C vs KD) p= 0.009 (CoV2+ vs MIS-C)
Hb, g/dL (range)	13 (12-14)	12.1 (12.1-12.1)	10.8 (8.8-11.2)	11.9 (11.3-12.4)	p<0.0001 (CoV2+ vs KD); p= 0.001 (MIS-C vs KD)
CRP, mg/dL (range)	0.1 (0.04-0.7)	5.3 (3.6-15.5)	11.3 (7.6-20.7)	0.00 (0.00-0.15)	p= 0.001 (MIS-C vs CoV2+); p<0.0001 (CoV2 vs KD) p<0.01 HC vs MIS.C and KD.
Ferritin, ng/mL (range)	58 (37.5-116)	2431 (668-18370)	189.5 (131.5-297.3)	n.a.	p= 0.0028 (MIS-C vs CoV2+) p= 0.0008 (MIS-C vs KD) p=0.0009 (CoV2+ vs KD)
ALT, UI/L (range)	17.5 (12-22.5)	54 (16-184.3)	43.5 (28.3-89.8)	n.a.	n.s.
AST, UI/L (range)	45.5 (29-49.5)	52.5 (18.2-116.8)	32.5 (25.3-56.8)	n.a.	n.s.
Albumin, g/dL (range)	4.4 (3.8-4.7)	4.8 (2.9-5)	3.7 (3.3-4.0)	n.a.	p<0.0001 (CoV2+ vs KD)
Sodium, mEq/L (range)	138 (137-139.3)	133 (131.3-137)	136.0 (134.0-137.0)	n.a.	p<0.0001 (CoV2+ vs KD)
Triglycerides, mg/ dL (range)	122.5 (71.2-180)	196 (124-305)	169.5 (117.0-238.8)	n.a.	p= 0.04 (CoV2+ vs KD)

Table 1. Laboratory test were presented as median, 25th-75th centiles. T-test and Mann-Whitney test were used for comparison between parametric and not parametric data respectively.

Hyperinflammation during MIS-C differs from that of severe, acute COVID-19

In adults and the elderly, the main cause of severe disease and death due to COVID-19 is uncontrolled immune activation and hyperinflammation (Vardhana and Wolchok, 2020). This life-threatening condition requires urgent management and the immunological aspects of this process is under intense investigation (Kuri-Cervantes et al., 2020; Mathew et al., 2020; Rodriguez et al., 2020). A number of clinical trials are ongoing to test immunomodulatory strategies to calm the cytokine storm in severe COVID-19. Since MIS-C is a hyperinflammatory condition associated with COVID-19, but with a delayed presentation, the question is whether the nature of this hyperinflammatory state is similar to that in adults with severe disease and whether the same immunomodulatory treatments should be considered. We measured 180 plasma proteins in serum samples from children with mild SARS-CoV2, MIS-C and Kawasaki disease and compared these to cytokine profiles recently reported in adults with severe acute COVID-19 (Rodriguez et al., 2020). We performed PCA analysis to visualize the datasets (**Figure 2A**). Adults with acute COVID-19, both patients in the Intensive Care Unit (ICU) and floor (non-ICU) but all severely ill, had very different cytokine profiles from the children with MIS-C, mild SARS-

CoV2 and Kawasaki disease (**Figure 2A**). The main contributing features explaining this difference included IL-8 (**Figure 2B**), a chemokine recently shown to be associated with lymphopenia in severe COVID-19 cases (Zhang et al., 2020). Also, IL-7 levels are associated with lymphocyte counts and T-cell maintenance and IL-7 also contribute to the difference between acute COVID-19 hyperinflammation and MIS-C and Kawasaki disease (**Figure 2B**). Another key proteins differing among these groups is MMP-10 (**Figure 2B**) a protein involved in arterial disease (Martinez-Aguilar et al., 2015), which is intriguing since both MIS-C and Kawasaki disease are disease with strong vasculitis components. The MIS-C and Kawasaki hyperinflammatory states partially overlap but are segregated from children with mild COVID-19 (**Figure 2A**).



Figure 2. MIS-C hyperinflammation differs from severe acute COVID-19 hyperinflammation. (A) Principal components 1 and 2 show variation in cytokine profiles among adult COVID-19 patients with severe disease treated in intensive care units, ICU or not and children with COVID-19, MIS-C or Kawasaki disease. n=131 samples included and 120 unique proteins included in the analysis. (**B**) top 20 proteins mostly contributing to the PCs 1-2.

Differences in T-cell subsets in MIS-C and Kawasaki disease

To better understand the hyperinflammation in MIS-C and Kawasaki disease we assessed peripheral blood mononuclear cell (PBMC) phenotypes by flow cytometry. Samples were collected at hospital admission, prior to treatment and reflect cellular states during the immune response. We found differences in the distributions of subpopulations of $CD4^+$ T-cells as defined by the expression of CD45RO and CD27, and the frequency of T-follicular helper cells (T_{FH}) expressing the chemokine receptor CXCR5 (**Figure 3A**). Total T-cell frequencies were lower in both types of hyperinflammatory patients, MIS-C and Kawasaki disease (**Figure 3A**). Within the $CD4^+$ T-cell compartment, MIS-C patients and children with

mild SARS-CoV2+ infection had similar subset distributions, indicating that differences seen in relation to healthy children could be related to the SARS-CoV2 infection itself (**Figure 3C-E**). Both SARS-CoV2 experienced groups of patients had higher abundances of central memory (CM) and effector memory (EM) CD4⁺ T-cells, but fewer naïve CD4⁺ T-cells as compared to Kawasaki disease patients (**Figure 3C-E**). Follicular helper T-cells, important players in germinal center reactions and supporters of B-cell responses were reduced in SARS-CoV2 experienced children, both with and without MIS-C, but not in Kawasaki disease patients (**Figure 3F**). CD57 marks terminally differentiated effector CD4+ T-cells and these have been shown to be reduced in adult patients with severe acute COVID-19 and acute respiratory distress syndrome (Anft et al., 2020). In children with mild COVID-19 and children with MIS-C we find higher levels of these terminally differentiated cell when comparing to Kawasaki disease patients and healthy children (**Figure 3G**). This further emphasizes the hyperinflammation seen in acute, severe COVID-19 in adults, differ from that seen in MIS-C and these data also indicate some specific differences between immune responses seen in MIS-C and Kawasaki disease patients.



Figure 3. CD4 T-cell subsets in COVID-19 and MIS-C. (**A**) Gating schema to identify CD4⁺ T-cell subsets from peripheral blood mononuclear cells. (**B**) CD4⁺ T-cells as a fraction of lymphocytes, (**C-G**) fraction of CD4⁺ T-cell subsets (%) in the indicated patient group. Black lines indicate statistical tests and p-values across indicated populations.

Unraveling the cytokine storm in MIS-C and Kawasaki disease

To further investigate the details of the hyperinflammatory immune responses occurring in MIS-C and Kawasaki disease patients, we performed Olink assays on plasma samples from these same patients as discussed above. We measured 180 unique proteins using two Olink panels (**Key Resource Table**) and filtered out proteins with >30% measurements below the threshold of detection**,** resulting in 121 plasma proteins used for principal component analysis (PCA) (**Figure 4A**). We find that healthy children and children infected with SARS-CoV2 without MIS-C largely overlapped, underscoring the mild infection in these children (**Figure 4A**). As shown by the blown up PC2 vs. 3 plot, MIS-C and Kawasaki hyperinflammatory states overlap but we also included samples collected after treatment of MIS-C patients with intravenous immunoglobulins, corticosteroids and IL1RA (**Figure 4A**). Two of three patients with MIS-C shifted their cytokine profiles post-treatment back to the healthy state (**Figure 4A**). Since PC2 best discriminated hyperinflammatory MIS-C and Kawasaki disease states from healthy children, we focused on the contributing features (loadings) of PC2 (**Figure 4B**). We find that elevated IL-6, IL-17A, CXCL10 contributed the most to the cytokine storm (**Figure 4C**). IL-17A is important in Kawasaki disease (Jia et al., 2010), but was significantly lower in MIS-C patients, indicating a difference in the underlying immunopathology (**Figure 4C**). In contrast, the top negative contributors were NT3, Stem cell factor (SCF) and TWEAK, a negative regulator of IFNγ and overall Th1-type immune response (Maecker et al., 2005). As a regulator of angiogenesis, TWEAK is also an interesting given the vasculitis component of Kawasaki disease and MIS-C (**Figure 4D**).

We also identified additional plasma proteins distinguishing MIS-C from Kawasaki. Apart from IL-17A, DCBLD2, also called ESDN, was more abundant in Kawasaki disease than MIS-C. This protein has been shown to be secreted by endothelial cells attacked by allogeneic immune cells after heart transplantation (Sadeghi et al., 2007) and in balloon dilated carotid arteries (Kobuke et al., 2001). Also, the metalloproteinase MMP-10 was higher in Kawasaki disease than MIS-C and MMP-10 is a biomarker of peripheral arterial disease correlating with disease severity (Rodriguez et al., 2008). Collectively, these findings indicate more arterial involvement in Kawasaki than MIS-C, and also a stronger IL-17A type cytokine storm in Kawasaki disease than in MIS-C.

Multiomic signatures place MIS-C at the intersection of COVID-19 and Kawasaki disease

To understand the interaction among different immune system components, their coregulation and relationship with disease, we applied Multiomics Factor Analysis (MOFA)(Argelaguet et al., 2019). We integrated immune cell frequencies and plasma protein concentrations measured in the same samples and search for latent vectors that best explain the combined variance across these datatypes. We found ten such latent factors with variable contributions from cell and protein measurements (**Figure 5A-B**). The first such factor separated Kawasaki disease samples from both groups of SARS-CoV2 infected children (MIS-C and CoV2+) (**Figure 5C**). The contributing features, both cells and proteins contributing to Factor 1, confirmed previous results of hyperinflammatory responses in Kawasaki dominated by IL-6, IFNγ and the corresponding cell subset changes (**Figure 5D**). Conversely, factor 5 discriminated the extremes of Kawasaki vs. mild SARS-CoV2+ infections and places MIS-C at the middle of these polar opposites (**Figure 5E**). This integrative analysis allow us to identify sets of features that best identify and discriminate these groups. Here, such features are the frequencies of naïve and central memory CD4+ T-cells (**Figure 5D**), and cytokines TGFβ and CXADR3 (**Figure 5E**). Such a reduced measurement set could be assessed for diagnostic and predictive purposes in larger sets of patients and could prove helpful as current diagnostic procedures rely solely on criteria that are often subjective and not always easy to quantify.



Figure 4. Overlapping cytokine profiles in Kawasaki and COVID-19 associated Kawasaki. (**A**) Principal component analysis of top 5 components explaing 63.5% of the variance in plasma concentrations of 121 proteins. PC2 vs 3 separate children with Kawasaki (n=28) and MIS-C (n=3) from healthy children (n=12) and SARS-CoV2+ children without hyperinflammation (n=41). (**B**) Proteins mostly explaining (highest loading for) PC2. (**C-D**) Raw (NPX) values for top proteins (loading) in PC2. (**E**) Raw (NPX) values of three proteins significantly different between Kawasaki and MIS-C.



Figure 5. Multiomic immune system differences among disease groups. (A) Fraction of variance explained by 10 latent factors, (**B**) Fraction of variance explained by data type, (**C**) Samples distributed across the top five latents factors. (**D**) Top contributing features for factor 1 and (**E**) factor 5 respectively.

Autoantibody profiling reveals candidate antigens

Several studies have proposed autoantibodies as an element of the immunopathology of Kawasaki disease (Sakurai, 2019). An external trigger, likely in the form of a virus is indicated by epidemics of Kawasaki disease, and direct evidence of antiviral antibody responses, particularly targeting viral particles in inclusion bodies in the respiratory epithelium have been reported (Rowley et al., 2008). Autoantibodies targeting endothelial cells can activate IL-6 production by endothelial cells in vitro (GRUNEBAUM et al., 2002), but a possible role of autoantibodies in MIS-C is unknown. To search for possible role for autoantibodies in MIS-C, we screened patient serum samples against 9341 human protein antigens from 7669 unique proteins using protein arrays (Zhu et al., 2001) (ProtoArray v5.1, PAH05251020, ThermoFisher, Waltham, Mass). As expected, the autoantibody signals were low for the vast majority of antigenic targets (Landegren et al., 2015), and the overall distributions were similarly low across disease groups and controls (**Figure 6A**). We calculated fold-change differences among MIS-C patient samples and healthy children and ranked proteins. Using this ranked list, we performed gene set enrichment analysis (GSEA)(Subramanian et al., 2005) to enriched groups of proteins and the functional roles of such autoantibody targets. We found that processes involving heart development, immune response regulation and blood vessel development dominated among the top autoantibody targets (**Figure 6B**). These findings are in agreement with the clinical presentation of MIS-C patients who often present with troponin release indicative of myocarditis, and in severe cases cardiogenic shock (Whittaker et al., 2020). We focused on the group of proteins involved in Cardiac ventricle development given its manageable size and strong enrichment among autoantibody targets (**Figure 6C**). The top protein in this category was RBPJ, a DNA-binding factor that regulates several pro-angiogenic programs in the heart (Díaz-Trelles et al., 2016) and is also involved in Notch-signaling and peripheral tolerance mediated by regulatory T-cells (Charbonnier et al., 2015). We found that all three MIS-C patients in our cohort, and a couple of Kawasaki disease patients had elevated levels of autoantibodies to two different epitopes of RBPJ (**Figure 6D**). Another protein targeted by autoantibodies in MIS-C and some Kawasaki disease patients was Endoglin, a glycoprotein expressed by endothelial cells and necessary for structural integrity of arteries and when disrupted known to give rise to the disease Hereditary hemorrhagic telangiectasia, a disease characterized by multisystemic vascular dysplasia (McAllister et al., 1994). All three MIS-C patients had elevated levels of autoantibodies targeting Endoglin above the median in healthy controls (**Figure 6E**). Also,

a number of Kawasaki disease patients had similar autoantibody reactivities as well as two of the healthy children (**Figure 6E**). Using data from the human protein atlas (Uhlen et al., 2015), we found that Endoglin protein expression is seen predominantly in the endothelium (**Figure 6F**). On blood immune cells, mostly monocytes express Endoglin (Uhlen et al., 2019), and overall the tissue with the highest Endoglin mRNA expression is the heart muscle (**Figure 6G**). Collectively these findings make Endoglin an interesting possible autoantibody target in MIS-C and in a subset of patients with Kawasaki disease and more detailed investigation will be required to further investigate the relevance of these autoantibodies.

DISCUSSION

The SARS-CoV-2 virus infects children at a similar rate as adults (Jones et al., 2020), but the disease COVID-19 is very mild in the overwhelming majority of infected children (Brodin, 2020). Despite the mild COVID-19 in children, recent reports of severe hyperinflammatory disorders developing 1-2 months after the acute infection with SARS-CoV2 are cause for much concern. This Multisystem Inflammatory Syndrome in Children associated with COVID-19 (MIS-C) also called Pediatric multisystem inflammatory syndrome, temporally associated with COVID-19 (PIMS-TS) have now been reported in more than 100 children worldwide and the numbers are increasing (Cheung et al., 2020; Riphagen et al., 2020; Verdoni et al., 2020; Whittaker et al., 2020).

Here we have combined high-dimensional analysis methods to uncover multiple aspects of the hyperinflammatory response in children with MIS-C. We find similarities with the immune response in Kawasaki disease, but also important differences, such as the IL-17A mediated hyperinflammation in Kawasaki disease, but not MIS-C. In addition, differences in T-cell subsets and cytokine mediators place MIS-C at the intersection in-between the immune states of Kawasaki disease and acute immune responses to SARS-CoV2 infection and the hyperinflammation seen in adults with severe COVID-19. We also find higher levels of biomarkers associated with arteritis and coronary artery disease in Kawasaki disease than in MIS-C suggesting a more diffuse endothelial involvement and immunopathology in MIS-C than in Kawasaki disease. Finally, we perform global autoantibody screening and find strong enrichment in MIS-C of autoantibodies to proteins involved in immune response regulation and structural proteins in the heart, in particular the glycoprotein Endoglin. These data suggest possible targets of autoimmune attack in the vasculature in general and in the

heart in particular of possible immunopathological importance. Further studies will be required to test these hypotheses. The hypothesis that autoantibodies contribute to the pathology in MIS-C is supported by the efficacy of intravenous immunoglobulin in MIS-C, a common approach to activate inhibitory Fc-receptors and prevent membrane-attack complexes by complement factors and thereby rapidly mitigate autoantibody-mediated pathology (Mackay et al., 2001).

Our results of lymphocyte subsets with lower naïve CD4+ T-cell, T_{FH} and increases in central and effector memory subpopulations in MIS-C as compared to Kawasaki disease patients could be explained by differences in patient age as immune cell proportions change with age even in healthy children (Olin et al., 2018; Schatorjé et al., 2012). At the same time, several studies have indicated defective T-cell responses as a central aspect of severe COVID-19 in adult patients (Vardhana and Wolchok, 2020). We find expanded CD57+ CD4+ T cells often representing immunosenescent and dysregulated T cells in both MIS-C and SARS-CoV2+ children with mild infections, suggesting that this might be a direct consequence of the SARS-CoV2 infection common to these children. Additional studies in mild and especially asymptomatic COVID-19 cases are required to investigate this hypothesis further.

Treatments of MIS-C have mostly followed protocols used in atypical Kawasaki disease given the overlapping presentation between these patients and children with MIS-C. The data presented here present a more complex picture with both shared features and clear differences that could influence strategies for treating these conditions. Kawasaki, but not MIS-C has a strong IL-17A upregulation and thus severe Kawasaki disease cases could potentially benefit from repurposing of IL-17A blocking agents such as Secukinumab used in Psoriasis, Rheumatoid arthritis and uveitis (Hueber et al., 2010). Such a strategy is unlikely to work in MIS-C where we find low IL-17A levels. In contrast the children in this study with MIS-C were treated with a combination of intravenous immunoglobulins (IVIG), corticosteroids and recombinant IL-1-receptor antagonist, IL-1RA (Anakinra). This same strategy has proven very effective in a handful of MIS-C patients treated in Sweden (manuscript in preparation). The cytokine profiles before and after this treatment show full reversal of the hyperinflammatory state in two of three MIS-C patients (**Figure 4A**). This treatment approach is also compatible with the data reported here. IVIG can neutralize some of the immunopathological effects of autoantibodies found, while corticosteroids provide

general immunosuppression and IL-1RA neutralizes the strong IL-1 response likely elicited by endothelial cells and innate immune cells recruited to the site of injury. Other treatment strategies reported include TNFα blockade (Infliximab) (Whittaker et al., 2020), but compared to adults with acute COVID-19, TNFa levels are lower in MIS-C (**Figure 2**) and also when comparing TNFα-levels in MIS-C to that of healthy children we find no elevated levels (**Supplementary Figure 2**), suggesting that TNFa-blockade will not be useful to mitigate MIS-C. Also, IL-6 blockade is a candidate treatment strategy already used in acute COVID-19 but we find highly variable IL-6 levels in MIS-C with 2/3 patients having normal IL-6 levels even during acute hyperinflammation (**Figure 4C)**. We therefor suspect that blocking IL-6 might not be universally effective in MIS-C patients. Overall the data presented here suggest novel directions for future work towards more mechanistic understanding of the immunopathology in MIS-C and development of novel immunomodulatory therapies that can mitigate the effects of hyperinflammatory disease in children during the COVID-19 pandemic.



Figure 6. Autoantibodies in MIS-C, Kawasaki and healthy children. (**A**) Overall antibody binding intensities against 9341 antigens from 7669 human proteins. Colored by sample group. (**B**) autoantibody antigens in MIS-C vs. healthy children ranked by fold-change difference and subject to gene set enrichment analysis (GSEA). (**C**) Enrichment score along the ranked order of genes for the GO:0003231, Cardiac ventricle development. (**D**) Autoantibodies targeting two different epitopes of RBPJ.(**E**) Autoantibodies targeting the glycoprotein Endoglin. (F) Immunohistochemistry staining of Endoglin in skin shows expression in endothelium. Image courtesy of Human Protein Atlas (http://www.proteinatlas.org)(antibody: HPA067440). (**G**) Normalized Endoglin (mRNA) expression among tissues within the human protein atlas database.

STAR METHODS

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to Petter Brodin (petter.brodin@ki.se). Raw data is available for download: https://ki.app.box.com/s/j3hgvdmkhvhv40gph8snixjgxcz0zpuj and scripts to reproduce the analyses are available through GitHub: https://github.com/Brodinlab/MIS-C_manuscript

Study Participants and Sample collection

Forty-four SARS-CoV2 infected children were enrolled within the CACTUS study at Bambino Gesù children hospital between March 17th and May 15th 2020. Diagnostic tests for SARS-CoV-2 infection are reported below. Four of the 44 children found to be SARS-CoV2+ by PCR herein were classified as having MIS-C based on the WHO definition (https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19). In summary this states that children and adolescents between 0 and 19 years old, with fever > 3 days, and displaying 2 signs among: i) rash or bilateral non purulent conjunctivitis or mucocutaneous inflammation signs, ii) hypotension or shock, iii) Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including ECHO findings or elevated Troponin/NT-proBNP), iv) evidence of coagulopathy (by PT, PTT, elevated d-Dimers), v) acute gastrointestinal problems (diarrhea, vomiting, or abdominal pain); AND elevated markers of inflammation such as ESR, C-reactive protein, or procalcitonin; AND no other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes; AND evidence of SARS-CoV2 infection (RT-PCR or serology positive), or likely exposure to COVID-19 patient. With regards to the MIS-C only 3 out of 4 patients were analyzed for deep immunology studies since one patient died due to cardiac complications after surgery during the study duration. Twenty-eight children diagnosed with KD were enrolled in the acute phase of the disease at the Academic Department of Pediatrics, Division of Immune and Infectious Diseases at Bambino Gesù Children's Hospital (OPBG) between September 2017 and June 2019, well before the COVID-19 pandemic hit Europe. KD diagnosis was made according to the 2017 criteria of the American Heart association, including both the complete and incomplete types. Fever onset was considered as the first day of the acute KD phase. Twelve healthy controls (HC) were recruited at OPBG. Demographic and clinical data of all the patients are summarized in Table 1. The OPBG Ethics Committees approved both studies and informed consent was obtained from parents or guardians of all patients.

Autoantibody analyses in APS-1 patients were approved by Ethical board of Stockholm (Permit: 2016/2553-31/2).

Confirmation of SARS-CoV-2 infection

All patients enrolled in the CACTUS study with nasopharyngeal swab tested positive for SARS-CoV-2 nucleic acid using reverse-transcriptase qualitative PCR assay were considered confirmed cases of SARS-CoV-2 infection. In addition, all serum samples of COVID19+ were investigated for presence of SARS-CoV-2 antibodies. IgG antibodies were quantitatively tested by LIAISON® SARS-CoV-2 S1/S2 IgG test (Diasorin).

Serum protein profiling

Serum proteins were analyzed using a multiplex technology based upon proximity-extension assays (Lundberg et al., 2011). Briefly, each kit consisted of a microtiter plate for measuring 92 protein biomarkers in all 88 samples and each well contained 96 pairs of DNA-labeled antibody probes. To minimize inter- and intra-run variation, the data were normalized using both an internal control (extension control) and an inter-plate control, and then transformed using a pre-determined correction factor. The pre-processed data were provided in the arbitrary unit Normalized Protein Expression (NPX) on a log2 scale and where a high NPX represents high protein concentration.

Autoantibody profiling

Serum autoantibody reactivity was studied using full-length human protein arrays (ProtoArray v5.1, PAH05251020, ThermoFisher)(Zhu et al., 2001). Protein arrays were probed with serum at a dilution of 1:2000, and otherwise followed the protocol provided by the manufacturer for immune response biomarker profiling. Protein arrays were first incubated with blocking buffer (PA055, Life Technologies) for 1 hour, followed by 90 min incubation with serum at 1:2000 dilution, and 90 min incubation with detection antibodies: Alexa Fluor 647 goat anti-human IgG antibody (A21445, ThermoFisher) at 1:2000 dilution and Dylight 550 goat anti-GST (#DY550011-13-001, Cayman Chemicals) at 1:10,000 dilution. The LuxScan HT24 (BioCapital) microarray scanner was used. All analyses of autoantibody reactivities were performed using background-subtracted mean signal values of protein duplicates of the human IgG channel.

Flow Cytometry analysis of T cell subsets

Blood samples from KD and SARS-CoV2+ patients were collected at the time of diagnosis and with regards to KD, always before Intravenous immunoglobulin administration. After ficoll, PBMCs and plasma samples were stored in liquid nitrogen or at -20°C, respectively, in Nunc Cryotubes (Merk KGaA, Darmstadt, Germany). Flow cytometry was performed for 30 patients, and isolated PBMCs were stained with LIVE/DEAD™ Fixable Near-IR Dead Cell Stain Kit (for 633 or 635 nm excitation, ThermoFisher, Waltham, Massachusetts, US) for 15 minutes at 4°C. Then, the cells were washed in wash buffer (phosphate-buffer saline with 1% bovine serum albumin) and stained for 30 minutes at 4°C with anti-hCD3 PE-CF594, anti-hCD4 BV510, anti-hCD25 PE, anti-hCD45RO-PerCP-Cy 5.5, anti-hCD27 V450, anti-hCD57 APC (all from BD Biosciences, Milan, Italy), anti-hCD127 PE-Cy7, anti-hPD1 BV711 (all from Biolegend, San Diego, CA). Data acquired by CytoFLEX cytometer (Beckman Coulter, Milan, Italy) were analyzed by FlowJo software v.10 (Treestar Software, Ashland, Oregon, USA). Statistical comparisons were performed with paired or unpaired nonparametric Mann-Whitney U test or t-tests.

Flow cytometry data analysis

Data analysis of flow cytometric frequencies was performed using R (version 3.6.2). To explore the clusters in different groups, we used the principal component analysis (PCA) and visualized the top two principal components. Statistical comparisons between two groups were performed with t-test if both distributions were approximately normal or, conversely, with the Wilcoxon nonparametric test. In both cases, the normality of the distributions was tested with the D'Agostino-Pearson test. P-values less than 0.05 were considered to be statistically significant. MOFA was performed with the MOFA+ package (version 1.0) in the R statistical environment (Argelaguet et al., 2019). With respect to clinical and routine laboratory data, median and interquartile range (IQ) for continuous variables were shown in table 1. Continuous laboratory data (total blood count, CRP, AST, ALT, albumin, sodium, ferritin, triglycerides) and statistical comparison among different groups were performed with Mann-Whitney U test. Graphpad Prism 8 software was used for statistical analysis of demographic and routine laboratory blood tests.

ACKNOWLEDGMENTS

We would like to acknowledge all patients and guardians who decided to participate to the study. We thank all the CACTUS study nurses team of the COVID-19 Center of "Bambino Gesù "Children's Hospital" and Jennifer Faudella for her administrative assistance. We

thank SciLifeLab Plasma Profiling Facility for generating Olink data and the SciLifeLab autoimmunity profiling facility for instrument support.

Conflict of interest: Authors declare no conflict of interest.

SOURCES OF FUNDING

This work was made possible by a grant from Knut and Alice Wallenberg Foundation (KAW) to SciLifeLab as well as donations from Bure Equity AB, and Jonas and Christina af Jochnick Foundation to Karolinska Institutet and P.B. The authors are also grateful for support from Children's Hospital Bambino Gesù, ricerca corrente 2020 to NC and ricerca corrente 2019 to PP.

REFERENCES

Anft, M., Paniskaki, K., Blazquez-Navarro, A., Doevelaar, A.A.N., Seibert, F., Hoelzer, B., Skrzypczyk, S., Kohut, E., Kurek, J., Zapka, J., et al. (2020). COVID-19 progression is potentially driven by T cell immunopathogenesis. Medrxiv 2020.04.28.20083089.

Argelaguet, R., Arnol, D., Bredikhin, D., Deloro, Y., Velten, B., Marioni, J.C., and Stegle, O. (2019). MOFA+: a probabilistic framework for comprehensive integration of structured single-cell data. Biorxiv 837104.

Brodin, P. (2020). Why is COVID-19 so mild in children? Acta Paediatr.

Charbonnier, L.-M., Wang, S., Georgiev, P., Sefik, E., and Chatila, T.A. (2015). Control of peripheral tolerance by regulatory T cell-intrinsic Notch signaling. Nat Immunol *16*, 1162–1173.

Cheung, E.W., Zachariah, P., Gorelik, M., Boneparth, A., Kernie, S.G., Orange, J.S., and Milner, J.D. (2020). Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City. Jama *324*.

Díaz-Trelles, R., Scimia, M.C., Bushway, P., Tran, D., Monosov, A., Monosov, E., Peterson, K., Rentschler, S., Cabrales, P., Ruiz-Lozano, P., et al. (2016). Notch-independent RBPJ controls angiogenesis in the adult heart. Nat Commun *7*, 12088.

GRUNEBAUM, E., BLANK, M., COHEN, S., AFEK, A., KOPOLOVIC, J., MERONI, P.L., YOUINOU, P., and SHOENFELD, Y. (2002). The role of anti-endothelial cell antibodies in Kawasaki disease - in vitro and in vivo studies. Clin Exp Immunol *130*, 233–240.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet *395*, 497–506.

Hueber, W., Patel, D.D., Dryja, T., Wright, A.M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M.H., Group, P.S., et al. (2010). Effects of AIN457, a Fully Human

Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis. Sci Transl Med *2*, 52ra72-52ra72.

Jia, S., Li, C., Wang, G., Yang, J., and Zu, Y. (2010). The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease: Th17/Treg imbalance in Kawasaki disease. Clin Exp Immunol *162*, 131–137.

Jones, T.C., Mühlemann, B., Veith, T., Biele, G., Zuchowski, M., Hoffmann, J., Stein, A., Edelmann, A., Corman, V.M., and Drosten, C. (2020). An analysis of SARS-CoV-2 viral load by patient age. Medrxiv 2020.06.08.20125484.

Kobuke, K., Furukawa, Y., Sugai, M., Tanigaki, K., Ohashi, N., Matsumori, A., Sasayama, S., Honjo, T., and Tashiro, K. (2001). ESDN, a Novel Neuropilin-like Membrane Protein Cloned from Vascular Cells with the Longest Secretory Signal Sequence among Eukaryotes, Is Up-regulated after Vascular Injury. J Biol Chem *276*, 34105–34114.

Kuri-Cervantes, L., Pampena, M.B., Meng, W., Rosenfeld, A.M., Ittner, C.A.G., Weisman, A.R., Agyekum, R., Mathew, D., Baxter, A.E., Vella, L., et al. (2020). Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection. Biorxiv 2020.05.18.101717.

Landegren, N., Sharon, D., Shum, A.K., Khan, I.S., Fasano, K.J., Hallgren, Å., Kampf, C., Freyhult, E., Ardesjö-Lundgren, B., Alimohammadi, M., et al. (2015). Transglutaminase 4 as a prostate autoantigen in male subfertility. Sci Transl Med *7*, 292ra101.

Lu, X., Zhang, L., Du, H., Zhang, J., Li, Y.Y., Qu, J., Zhang, W., Wang, Y., Bao, S., Li, Y., et al. (2020). SARS-CoV-2 Infection in Children. New Engl J Med *382*, 1663–1665.

Lundberg, M., Eriksson, A., Tran, B., Assarsson, E., and Fredriksson, S. (2011). Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. Nucleic Acids Res *39*, e102–e102.

Mackay, I.R., Rosen, F.S., Kazatchkine, M.D., and Kaveri, S.V. (2001). Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune Globulin. New Engl J Med *345*, 747–755.

Maecker, H., Varfolomeev, E., Kischkel, F., Lawrence, D., LeBlanc, H., Lee, W., Hurst, S., Danilenko, D., Li, J., Filvaroff, E., et al. (2005). TWEAK Attenuates the Transition from Innate to Adaptive Immunity. Cell *123*, 931–944.

Martinez-Aguilar, E., Gomez-Rodriguez, V., Orbe, J., Rodriguez, J.A., Fernández-Alonso, L., Roncal, C., and Páramo, J.A. (2015). Matrix metalloproteinase 10 is associated with disease severity and mortality in patients with peripheral arterial disease. J Vasc Surg *61*, 428–435.

Mathew, D., Giles, J.R., Baxter, A.E., Greenplate, A.R., Wu, J.E., Alanio, C., Oldridge, D.A., Kuri-Cervantes, L., Pampena, M.B., D'Andrea, K., et al. (2020). Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions. Biorxiv 2020.05.20.106401.

McAllister, K.A., Grogg, K.M., Johnson, D.W., Gallione, C.J., Baldwin, M.A., Jackson, C.E., Helmbold, E.A., Markel, D.S., McKinnon, W.C., Murrel, J., et al. (1994). Endoglin, a TGF-β

binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet *8*, 345–351.

Olin, A., Henckel, E., Chen, Y., Lakshmikanth, T., Pou, C., Mikes, J., Gustafsson, A., Bernhardsson, A.K., Zhang, C., Bohlin, K., et al. (2018). Stereotypic Immune System Development in Newborn Children. Cell *174*, 1277-1292.e14.

Parri, N., Lenge, M., Buonsenso, D., and Group, C.I. in P.E.D. (CONFIDENCE) R. (2020). Children with Covid-19 in Pediatric Emergency Departments in Italy. New Engl J Medicine.

Riphagen, S., Gomez, X., Gonzalez-Martinez, C., Wilkinson, N., and Theocharis, P. (2020). Hyperinflammatory shock in children during COVID-19 pandemic. Lancet.

Rodriguez, J.A., Orbe, J., Lizarrondo, S.M. de, Calvayrac, O., Rodriguez, C., Martinez-Gonzalez, J., and Paramo, J.A. (2008). Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Front Biosci *13*, 2916.

Rodriguez, L., Pekkarinen, P., Tadepally, L.K., Tan, Z., Consiglio, C.R., Pou, C., Chen, Y., Mugabo, C.H., Quoc, A.N., Nowlan, K., et al. (2020). Systems-level immunomonitoring from acute to recovery phase of severe COVID-19. Medrxiv 2020.06.03.20121582.

Rowley, A.H., Baker, S.C., Orenstein, J.M., and Shulman, S.T. (2008). Searching for the cause of Kawasaki disease--cytoplasmic inclusion bodies provide new insight. Nat Rev Microbiol *6*, 394–401.

Sadeghi, M.M., Esmailzadeh, L., Zhang, J., Guo, X., Asadi, A., Krassilnikova, S., Fassaei, H.R., Luo, G., Al-Lamki, R.S.M., Takahashi, T., et al. (2007). ESDN Is a Marker of Vascular Remodeling and Regulator of Cell Proliferation in Graft Arteriosclerosis. Am J Transplant *7*, 2098–2105.

Sakurai, Y. (2019). Autoimmune Aspects of Kawasaki Disease. J Invest Allerg Clin *29*, 251–261.

Schatorjé, E.J.H., Gemen, E.F.A., Driessen, G.J.A., Leuvenink, J., Hout, R.W.N.M. van, and Vries, E. de (2012). Paediatric Reference Values for the Peripheral T cell Compartment: T Lymphocyte Subsets in Children. Scand J Immunol *75*, 436–444.

Shulman, S.T., and Rowley, A.H. (2015). Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatology *11*, 475–482.

Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. P Natl Acad Sci Usa *102*, 15545–15550.

Uhlen, M., Fagerberg, L., Hallstrom, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, A., Kampf, C., Sjostedt, E., Asplund, A., et al. (2015). Tissue-based map of the human proteome. Science *347*, 1260419–1260419.

Uhlen, M., Karlsson, M.J., Zhong, W., Tebani, A., Pou, C., Mikes, J., Lakshmikanth, T., Forsström, B., Edfors, F., Odeberg, J., et al. (2019). A genome-wide transcriptomic analysis of protein-coding genes in human blood cells. Sci New York N Y *366*.

Vardhana, S.A., and Wolchok, J.D. (2020). The many faces of the anti-COVID immune response. J Exp Medicine *217*.

Verdoni, L., Mazza, A., Gervasoni, A., Martelli, L., Ruggeri, M., Ciuffreda, M., Bonanomi, E., and D'Antiga, L. (2020). An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet.

Whittaker, E., Bamford, A., Kenny, J., Kaforou, M., Jones, C.E., Shah, P., Ramnarayan, P., Fraisse, A., Miller, O., Davies, P., et al. (2020). Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2. Jama *324*.

Zhang, X., Tan, Y., Ling, Y., Lu, G., Liu, F., Yi, Z., Jia, X., Wu, M., Shi, B., Xu, S., et al. (2020). Viral and host factors related to the clinical outcome of COVID-19. Nature 1–7.

Zhu, H., Bilgin, M., Bangham, R., Hall, D., Casamayor, A., Bertone, P., Lan, N., Jansen, R., Bidlingmaier, S., Houfek, T., et al. (2001). Global Analysis of Protein Activities Using Proteome Chips. Science *293*, 2101–2105.